CN102573915B - 流感血凝素组合物及其用途 - Google Patents

流感血凝素组合物及其用途 Download PDF

Info

Publication number
CN102573915B
CN102573915B CN201080019069.9A CN201080019069A CN102573915B CN 102573915 B CN102573915 B CN 102573915B CN 201080019069 A CN201080019069 A CN 201080019069A CN 102573915 B CN102573915 B CN 102573915B
Authority
CN
China
Prior art keywords
composition
seq
amino acid
ectodomain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080019069.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102573915A (zh
Inventor
M·巴赫曼
A·杰格勒纳
P·桑丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytos Biotechnology AG
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Publication of CN102573915A publication Critical patent/CN102573915A/zh
Application granted granted Critical
Publication of CN102573915B publication Critical patent/CN102573915B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201080019069.9A 2009-04-30 2010-04-30 流感血凝素组合物及其用途 Expired - Fee Related CN102573915B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09159262 2009-04-30
EP09159262.6 2009-04-30
PCT/EP2010/055944 WO2010125202A1 (en) 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof

Publications (2)

Publication Number Publication Date
CN102573915A CN102573915A (zh) 2012-07-11
CN102573915B true CN102573915B (zh) 2015-02-18

Family

ID=42790940

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080019069.9A Expired - Fee Related CN102573915B (zh) 2009-04-30 2010-04-30 流感血凝素组合物及其用途

Country Status (9)

Country Link
US (1) US20120263743A1 (enExample)
EP (1) EP2424570A1 (enExample)
JP (1) JP2012525134A (enExample)
CN (1) CN102573915B (enExample)
AU (1) AU2010243490A1 (enExample)
CA (1) CA2759873A1 (enExample)
NZ (1) NZ596058A (enExample)
SG (1) SG175382A1 (enExample)
WO (1) WO2010125202A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
AU2020234713A1 (en) 2019-03-13 2021-11-04 Generation Bio Co. Non-viral DNA vectors and uses thereof for expressing FVIII therapeutics

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005950A3 (en) * 1999-07-20 2001-08-02 Morphosys Ag Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
CN1582164A (zh) * 2001-11-07 2005-02-16 赛托斯生物技术公司 用于治疗骨病的抗原阵列
CN1599623A (zh) * 2001-09-14 2005-03-23 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
CN1668637A (zh) * 2002-07-17 2005-09-14 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
CN101227920A (zh) * 2005-07-19 2008-07-23 陶氏环球技术公司 重组流感疫苗
CN101325966A (zh) * 2005-10-18 2008-12-17 诺瓦瓦克斯股份有限公司 功能性流感病毒样颗粒(vlp)
CN101394864A (zh) * 2006-03-07 2009-03-25 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
CN101421302A (zh) * 2006-02-28 2009-04-29 遗传工程与生物技术中心 针对禽流感病毒的嵌合疫苗抗原

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
KR20060031607A (ko) * 2003-07-10 2006-04-12 사이토스 바이오테크놀로지 아게 패킹된 바이러스-양 입자
JP2008513035A (ja) * 2004-09-21 2008-05-01 サイトス バイオテクノロジー アーゲー Ａｐ２０５のコートタンパク質と抗原性ポリペプチドとの融合タンパク質を含んでなるウイルス粒子
AU2006279323B2 (en) * 2005-08-16 2013-08-01 Merck Sharp & Dohme Corp. Influenza recombinant subunit vaccine
NZ569741A (en) * 2005-12-14 2012-02-24 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US20070224205A1 (en) * 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005950A3 (en) * 1999-07-20 2001-08-02 Morphosys Ag Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
CN1599623A (zh) * 2001-09-14 2005-03-23 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
CN1582164A (zh) * 2001-11-07 2005-02-16 赛托斯生物技术公司 用于治疗骨病的抗原阵列
CN1668637A (zh) * 2002-07-17 2005-09-14 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
CN101227920A (zh) * 2005-07-19 2008-07-23 陶氏环球技术公司 重组流感疫苗
CN101325966A (zh) * 2005-10-18 2008-12-17 诺瓦瓦克斯股份有限公司 功能性流感病毒样颗粒(vlp)
CN101421302A (zh) * 2006-02-28 2009-04-29 遗传工程与生物技术中心 针对禽流感病毒的嵌合疫苗抗原
CN101394864A (zh) * 2006-03-07 2009-03-25 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法

Also Published As

Publication number Publication date
CA2759873A1 (en) 2010-11-04
EP2424570A1 (en) 2012-03-07
CN102573915A (zh) 2012-07-11
JP2012525134A (ja) 2012-10-22
US20120263743A1 (en) 2012-10-18
SG175382A1 (en) 2011-12-29
NZ596058A (en) 2013-08-30
AU2010243490A1 (en) 2011-11-24
WO2010125202A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
US20220305131A1 (en) Modified virus-like particles of cmv
RU2468034C2 (ru) Иммуногенные композиции и способы
CN103957891B (zh) 基于流感血凝素蛋白的新颖疫苗
JP6294828B2 (ja) インフルエンザウイルスワクチンおよびその使用
ES2385842T3 (es) Vacuna mejorada contra la gripe
CN101141979B (zh) 猫变应原融合蛋白及其用途
JP5654345B2 (ja) 多量体マルチエピトープインフルエンザワクチン
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
JP2023540486A (ja) 免疫原性コロナウイルス融合タンパク質および関連方法
Sun et al. Toward innovative veterinary nanoparticle vaccines
Zhang et al. Advances in protein subunit vaccines against H1N1/09 influenza
US12397050B2 (en) Universal mammalian influenza vaccine
CN102573915B (zh) 流感血凝素组合物及其用途
EP3599247A2 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
JP2018052953A (ja) インフルエンザウイルスワクチンおよびその使用
Cote-Cyr et al. Self-assembly of flagellin into immunostimulatory ring-like nanostructures as an antigen delivery system
US11535651B2 (en) Hepatitis B nanoparticle-based vaccine for influenza virus
RU2852174C1 (ru) Рекомбинантная вакцина против вируса гриппа а человека и способ ее получения
Kim et al. Hemagglutinin-displaying influenza nanovaccines: progress and promise
WO2025073874A1 (en) Vaccine composition comprising m2e nanoparticles and ha1 protein
HK40077650A (en) Modified virus-like particles of cmv
HK1255670B (zh) Cmv的修饰病毒样颗粒
BR112017008266B1 (pt) Partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv) e composição farmacêutica

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150218

Termination date: 20150430

EXPY Termination of patent right or utility model